This week, 16th may, 2018, the project "MULTIFLOW" subsidized by the Center for Industrial Technological Development under the FEDER INNTERCONECTA program and carried out by the companies Vitro, Master Diagnostica, Destina Genómica and Rekom Biotech has concluded. The closure of the project was carried out in Seville, in the Vitro facilities. The multidisciplinary team formed by the "MULTIFLOW" consortium has successfully completed all the technical objectives established in the project. From Rekom Biotech we thank our partners in the consortium for the great work and collaboration environment that has characterized the project since its beginnings.
Human cytomegalovirus (HCMV) is endemic to populations throughout the world, and 50-80% of the adults in developed nations are sero-positive for this virus. Commercial ELISAs for detecting IgG are very sensitive and specific. Nevertheless, there are several problems regarding IgM detection. One of the difficulties that the diagnostic laboratory has faced over the past 10 years is the lack of agreement between commercial tests for the detection of CMV-specific IgM. This lack of agreement has its roots in the different viral preparations used to detect IgM antibodies to CMV. Rekom Biotech has performed the design of a new CMV recombinant polyepitope chimeric antigen (RAG0109), composed by different sensitive and specific antigenic determinants from some CMV proteins. This recombinant polyepitope chimeric antigen was tested in parallel with other CMV bio-markers such as the Rekom Biotech CMV recombinant proteins pp150 (RAG0091), pp52 (RAG0090) and pp65 (RAG0016). The in house indirect IgM ELISA assay was carried out by using a battery of pre-validated sera with the commercial ELISA capture IgM test from Vidas:
Figure 1: Indirect IgM ELISA assay. Proteins were coating the plates at a final concentration of 1 µg/ml. All these experiments used anti-IgG as sorbent and anti-IgM-HRP. Sera were used in a 1:100 dilution. P means pre-validated sera by the Vidas test as positive; N means pre-validated sera by the Vidas test as negative.
These preliminary experiments suggest that the recombinant polyepitope chimeric antigen designed and produced by Rekom Biotech, RAG0109, recovers some pre-validated IgM positive sera which are not initially detected by two of the best antigens described in bibliography for CMV diagnosis: pp52 and pp150, showing the presence in merely one antigen of some important epitopes for this specific diagnostic.
To find more interesting information on regards recombinant antigen RAG0109, please click here.
Our commitment to ensure the highest quality level in the design and production of recombinant antigens continues after the implementation of the ISO:9001-2015 Standard.
Rekom Biotech attends to MEDLAB ASIA PACIFIC, from 2nd to 4th April, 2018, aiming to consolidate their presence in the Asian market. During the exhibition, our colleagues, Dr. Ana Camacho (CEO & CSO - PhD) and Rafael Texeira (Export Manager), met potential customers interested both in our recombinant antigens range and our custom-made design services. Furthermore, the new bio-allergens line was introduced and current customers from countries such as China, India or Japan were visited.
Rekom Biotech has again attended MEDICA, from 13rd to 16th November, 2017. This year we have presented our new range of recombinant allergen products, Bioallergens, in addition to our recombinant antigens most successful in evaluations for the development of a commercial diagnostic assay.